Sentinel Lymph Node in Endometrial Cancer. Reem Abdallah, MD American University of Beirut Medical Center
|
|
- Marshall Phillip Morton
- 5 years ago
- Views:
Transcription
1 Sentinel Lymph Node in Endometrial Cancer Reem Abdallah, MD American University of Beirut Medical Center
2 No disclosures
3 Percent of Cases by Stage 8% 4% 21% 67% Localized (confined to primary site) Regional (spread to regional LN) Distant (metastatic) year Relative Survival 95,3 68,2 48,5 16,9 (Accessed on January 31, 2016).
4 LN status: Prognostic value, guide adjuvant trt Role of Lymphadenectomy controversial Systematic LND not widely adopted around 30% Selective, systematic, none.
5 No LND 65% Low-risk Pelvic LN mets 9% ASTEC trial, Panici et al: no therapeutic benefit Morbidity of comprehensive LND
6 Selective Risk of nodal mets size, DOI, grade, LVSI As low as 2% in low risk and Up to 35% in high-risk
7 Comprehensive FS variable accuracy 25% with preop grade 1 will be upgraded on final path Avoid unnecessary adj trt Therapeutic value? SEPAL study, Chan 2006 SEER
8 Risk of nodal mets size, DOI, grade, LVSI As low as 2% in low risk and Up to 35% in high-risk FS variable accuracy 25% with preop grade 1 will be upgraded on final path Understaging vs overtrt
9 Understaging vs overtrt SLN mid option Node most likely to harbor mets SLN endometrial ca first introduced by Burke,1996 Advantages: avoid unecessary extensive LND of neg LN, associated morbidity, guide the need of adjuvant trt, detecting micromets, ultrastaging prognostic significance? No RCT re role of SLNB, no long-term survival data
10
11 Common Lymphatic Drainage 3% 36% 8% 30% 23%
12 Classical mapping
13
14
15 Techniques Radioactive tracer +/- Green or blue dye Sites of injection: Cervical (combined superficial (submucosal, 1 3 mm) and deep (stroma, 1 2cm)) Fundal subserosal Peritumoral hysteroscopic Courtesy of Abu-Rustum NR, Levine DA, Barakat RR, eds. Atlas of Procedures in Gynecologic Oncology, 3rd ed. London: Informa Healthcare; c2013, Memorial Sloan-Kettering Cancer Center.
16 Cervical Subserosal fundal Peritumoral Pros 1. Main lymphatic drainage: parametria 2. Easy, accessible 3. Rarely distorted 1. Better reflection of PA drainage (Detection of PASLN: 39% But Isolated PALN mets in literature <5%) Cons Detection Rates 1. Low PA detection (Superficial injection: DR 2%, Deep: DR 17%) 1. Not reflective of main lymphatic drainage 2. Rarely infiltrating fundal serosa % 45-75% One study 92%: 8 sites 1. More complicated 2. Disseminating malignant cells through tubes? % Studies including >100 cases had detection rate >80%
17 Pros 1. Main lymphatic drainage: parametria 2. Easy, accessible 3. Rarely distorted Cervical Subserosal fundal Peritumoral 1. Better reflection of PA drainage (Detection of PASLN: 39%) Cons 1. Low PA detection (Superficial injection: DR 2%, Deep: DR 17%) 1. Not reflective of main lymphatic drainage 2. Rarely infiltrating fundal serosa 1. More complicated 2. Disseminating malignant cells through tubes? Detection Rates % 45-75% One study 92%: 8 sites % Isolated PALN mets in literature <5% Studies including >100 cases had detection rate >80% Most recent studies, DR >92%
18 Metaanalysis (26 studies, 1101 SLN procedures) Mean SLN detected 2.6 (1-4.7) Bilaterality of SLN 61% (20%-81%) Detection Rate 78% (95% CI=73%--84%) Sensitivity 93% (95% CI=85% 100%) False Negative Rate 7% (0-14%) Pericervical injection Increase in detection rate (p 0.031) Hysteroscopic only injection Decrease in detection rate (p 0.045) Subserosal only injection Decrease in sensitivity (p 0.049) Kang S, Yoo HJ, Hwang JH, et al. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 2011;123:
19 Metaanalysis Studies>30pts SLN procedures 1572 Bilaterality of SLN (Range) 52% (19%-100%) Detection Rate (Range) 83% (62%-100%) Sensitivity (Range) 81% (43%-100%) Algorithm Sensitivity 95% (83%-100%) Pericervical injection DR 62%-100% Corporeal injection DR 73%-95% DR in studies >100 pts >80% Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):
20 Algorithm Peritoneal and serosal evaluation and washings Retroperitoneal evaluation Excision of all mapped SLNs with ultrastaging Any suspicious nodes must be removed regardless of mapping If no mapping on a hemi-pelvis, side-specific LND Para-aortic LND at the physician s discretion Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533
21 SLN alone Algorithm Sensitivity 85.1% 98.1% Negative Predictive Value 98.1% 99.8% False Negative Rate 14.9% 1.9% Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533
22 Algorithm Overall false false negative rate negative rate Overall Algorithm Author N (%) (%) sensitivity (%) sensitivity (%) Barlin (7/54) 2 (1/54) Ballester (3/20) 5 (1/20) How (3/11) 9 (1/11) Niikura (3/18) 6 (1/18) Torné 74 8 (1/13) 8 (1/13) Sawicki (1/2) 0 (0/2) Vidal (4/7) 14 (1/7) Delaloye (1/9) 0 (0/9) Solima (1/10) 0 (0/10) Lopez-de la 50 0 (0/3) 0 (0/3) Manzanara Bats (2/10) 0 (0/10) Lopes (6/11) 9 (1/11) Holloway (1/10) 10 (1/10) Mais (3/6) 17 (1/6) Mucke (1/6) 0 (0/6) Total (37/190) 5 (9/190) Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):
23 Dual Labelling Standard has been: Isotope+Blue Dye Detection rates: % Bilateral detection: 40-80% Combination was not shown to be significantly higher in metaanalysis
24 Radiolabeled Colloid-Tc99 Short Protocol: mci, 2-4 hrs preop Long Protocol: 2-4 mci, hrs preop Maximum accumulation in SLN: 1.5hrs Lymphoscintigram (2 hrs after injection, then every 30 min to detect SLN) Gamma probes
25 LSG- Long vs Short Protocol Whole (N=118) Short (N=44) Long (n=66) P Detection Rate 88 (74.6%) 30 (68.2%) 53 (80.3%) 0.22 Bilateral detection 44 (37.3%) 12 (27.3%) 29 (43.9%) 0.29 Preop LSG Paraaortic SLN Common iliac SLN Median number of SLN detected per patient Number of SLN detected 0 10 (22.7%) 8 (12.1%) 23 (34.8%) Detection Rate 102 (86.4%) 36 (81.8%) 59 (89.4%) 0.62 Bilateral detection 62 (52.5%) 21 (47.4%) 36 (54.5%) 0.89 Intraop Paraaortic SLN Common iliac SLN 1 (2.3%) 12 (27.3%) 2 (3%) 16 (24.2%) Number of SLN detected Frati et al. Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. Ann Surg Oncol (2015) 22:
26 LSG Short (N=44) Long (n=66) P Paraaortic SLN Common iliac SLN 0 10 (22.7%) 8 (12.1%) 23 (34.8%) % Number of SLN detected Preop LSG Number of PA SLN detected Number of common SLN iliac detected Paraaortic SLN Common iliac SLN 0 14 (9.5%) (27%) 34 (23%) (2.3%) 12 (27.3%) 2 (3%) 16 (24.2%) % 31% 3% Number of SLN detected Intraop Number of PA SLN detected 3 (3.3%) 4 (2.2%) % Number of common SLN iliac detected 13 (14.1%) 23 (12.5%) % Frati et al. Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. Ann Surg Oncol (2015) 22:
27 Colored Dye Isosulfan blue 1% (Lymphazurin), Methylene blue 1%, Patent blue 2.5% Under anesthesia in the OR 2-4 ml Slowly, 5-10 sec/quadrant Time to reach LN: 5 min Median stain time in the SLN: 21 min Allergic reactions < 5%
28 Indocyanine Green (ICG) Near-infrared fluorescence imaging 2-4 ml Main contraindication: iodine allergy DR in literature: % Bilateral mapping: 65-85% vs Blue dye: Higher overall detection rate (87% vs 71%; p = 0.005) Higher bilateral detection (65% vs 43%; p = 0.002) In particular, obese vs Tc99: Similar overall (87% vs 88%, p = 0.83) and bilateral (65% vs 71%,p = 0.36) detection
29 Combination ICG+Tc99 probably yields the best results
30 Pathology H&E If neg, Ultrastaging: Two 5 μm sections, at each of two levels 50 μm apart from each paraffin block H&E and IHC 4 slides/block +3-7% micromets Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrialcancer staging. Int J Gynecol Cancer 2013;23:968;
31 Terminology Definition Significance Macromets tumor clusters >2 mm Positive Micromets tumor clusters mm Positive Isolated tumor cells single tumor cells or clusters 0.2 mm Positive value and trt still controversial Isolated cytokeratinpositive cells only Rare isolated cytokeratin-positive cells not identified on corresponding H&Estained sections or do not demonstrate morphologic features of invasive ca Negative
32 DMI Grade 1 Grade 2 Grade 3 Total No Invasion < 50% invasion 50% invasion Total MM 1 ITC 1 n = 165 MM 2 ITC 4 n = 80 MM 0 ITC 2 n = 16 10/261= 3.8% MM 0 ITC 0 n = 39 MM 0 ITC 4 n = 62 MM 0 ITC 0 n = 15 4/116= 3.4% MM 0 ITC 0 n = 38 MM 0 ITC 6 n = 56 MM 1 ITC 2 n = 37 9/131 = 6.9% 2/242 = 0.8% 16/198 = 8.0% 5/68 = 7.4% 23/508 = 4.5% Maybe omit ultrastaging if no myometrial invasion Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrialcancer staging. Int J Gynecol Cancer 2013;23:968;
33 No MI DMI<50% Preop grade 1 H&E 0 MMs 1 ITCs 1 N=193 H&E 8 MMs 2 ITCs 7 N=130 Preop grade 2 H&E 1 MMs 0 ITCs 0 N=48 H&E 4 MMs 0 ITCs 1 N=56 Total 19/323 (5.9%) 6/104 (6.9%) Total 3/241 (1.2%) 22/184 (12.0%) 25/425 (5.9%) Low volume mets detected by ultrastaging: 10/184 (5.4%) Final grade 1 Final grade 2 Final grade 3 Total No MI DMI<50% Total H&E 0 MMs 1 ITCs 1 N=194 H&E 8 MMs 2 ITCs 4 N=108 16/302 (5.3%) 21/174 (12.0%) H&E 1 MMs 0 ITCs 0 N=42 H&E 4 MMs 0 ITCs 3 N=66 8/108 (7.4%) H&E 0 MMs 0 ITCs 0 N=5 H&E 0 MMs 0 ITCs 1 N=10 1/15 (6.7%) 3/241 (1.2%) 22/184 (12.0%) 25/425 (5.9%) Low volume mets detected by ultrastaging: 9/174 (5.2%) Kim et al.sentinel Lymph Node Mapping with Pathologic Ultrastaging: A Valuable Tool for Assessing Nodal Metastasis in Low-Grade Endometrial Cancer with Superficial Myoinvasion. Gynecol Oncol December ; 131(3)
34 Author N Proportion of metastatic patients detected only by ultrastaging (%) Micrometastases Isolated tumor cells Kim (23/64) 4 19 Ballester (9/20) 7 1 Desai (5/10) 5 Niikura (8/18) 5 3 Solima (6/10) 3 3 Bats (1/10) 1 Holloway (4/10) 2 2 Total (56/142) Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):
35
36 Are these low-volume mets true mets? Frimer et al. Micrometastasis of endometrial cancer to sentinel lymph nodes: Is it an artifact of uterine manipulation? Gynecologic Oncology 119 (2010)
37 MM/ITC (n=19) (%) No MM/ITC (n=145) (%) P value LVSI <0.001 Present 12 (63.2%) 22 (15.2) Absent 7 (36.8) 123 (84.8) Depth of myometrial invasion 0.01 None 4 (21) 83 (57.2) <50% 12 (63.2) 47 (32.4) 79% 50% 3 (15.8) 15 (10.3) Low-volume SLN mets (N=23) Routine H&E SLN mets (N=35) Routine H&E non-sln mets (N=35) LVSI + LVSI - 20 (87%) 3 (13%) 31 (89%) 4 (11%) 5 (83%) 1 (17%) Negative SLN (N=444) 76 (17%) 368 (83%) Frimer et al. Micrometastasis of endometrial cancer to sentinel lymph nodes: Is it an artifact of uterine manipulation? Gynecologic Oncology 119 (2010) Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrialcancer staging. Int J Gynecol Cancer 2013;23:968;
38 25 pts with SLN+
39 High Risk Pts Retrospective multicenter French study: L/IR (N=141, 78%) HR (N=39, 22%) p Detection Rate 88% 88% NS Bilaterality 64% 60% NS False Negative Rate, Overall 2.3% 20% % excluding unilateral detection Senti-Endo: False Negative Rate, Overall L/IR (N=90) HR (N=16) 0% 18% All were type II Naoura I et al. Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol Oncol Jan;136(1):60-4. Ballester, M. et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. mai 2011; 12:
40 Prospective, MD Anderson, early results Soliman SGO 2015: 60 patients, high risk Detection rate: 92.3% Bilaterality: 60.7% False Negative Rate: 0%
41 Algorithm Peritoneal and serosal evaluation and washings Retroperitoneal evaluation Excision of all mapped SLNs with ultrastaging Any suspicious nodes must be removed regardless of mapping If no mapping on a hemi-pelvis, side-specific LND Para-aortic LND at the physician s discretion Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533
42 SLN alone Algorithm Sensitivity 85.1% 98.1% Negative Predictive Value 98.1% 99.8% False Negative Rate 14.9% 1.9% Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533
43 Algorithm Overall false false negative rate negative rate Overall Algorithm Author N (%) (%) sensitivity (%) sensitivity (%) Barlin (7/54) 2 (1/54) Ballester (3/20) 5 (1/20) How (3/11) 9 (1/11) Niikura (3/18) 6 (1/18) Torné 74 8 (1/13) 8 (1/13) Sawicki (1/2) 0 (0/2) Vidal (4/7) 14 (1/7) Delaloye (1/9) 0 (0/9) Solima (1/10) 0 (0/10) Lopez-de la 50 0 (0/3) 0 (0/3) Manzanara Bats (2/10) 0 (0/10) Lopes (6/11) 9 (1/11) Holloway (1/10) 10 (1/10) Mais (3/6) 17 (1/6) Mucke (1/6) 0 (0/6) Total (37/190) 5 (9/190) Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):
44
45
46 Non-SLN if SLN positive? Positive non-sln, n (%) Negative non-sln, n (%) Total, n (%) SLN negative 0.6% All SLN mets 15 (34.8%) 28 (65.2%) 43 SLN metastasis >2 mm SLN metastasis 2 mm 14 (60.8%) 9 (39.2%) 23 (100%) 1 (5%) 19 (95%) 20 (100%) P < Touhami et al. Predictors of non-sentinel lymph node (non-sln) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecologic Oncology 138 (2015) 41 45
47 Frozen Section on SLN? 87/111 (78.5%) pts had intraop eval of SLN Intraop exam Technique used for intraop exam Frozen section (37) Final histology Positive Negative Positive 9 0 Negative 7 71 Final histology Positive Positive 6 0 Negative 1 30 Negative Sensitivity: 56.3 % (95 % CI, %) NPV: 91 % (95 % CI, %) Accuracy: 92 % (95 % CI, %) Sensitivity Macromets: 100% Sensitivity Micro/ITC:12.5% (7 FN/8) Sensitivity: 85.7 % (95 % CI, ), NPV:96.8 % (95 % CI: ) Accuracy:97.3 % (95 % CI: ) Imprint cytolog y Positive 3 0 Negative 6 41 Sensitivity: 33.3 % (95 % CI, ) NPV: 87.2 % (95 % CI, ) Accuracy: 88 % (95 % CI, %) Ballester M et al. Comparison of diagnostic accuracy of frozen section with imprint cytology for intraoperative examination of sentinel lymph node in early-stage endometrial cancer: results of Senti-Endo study. Ann Surg Oncol Oct;19(11):
48 46/268 (18.2%) pts had SLN sent for frozen Final histology of SLN (ultra-staging) Positive Negative Frozen section of SLN Positive 12 0 Negative 2 (1 macromet, 1 ITC) 35 Sensitivity: 85.7% (95% CI: 57.16%-97.80%) FNR: 14.3% Sensitivity for detecting macromets: 92.3% (95% CI: 63.90%-98.72%) Touhami et al. Predictors of non-sentinel lymph node (non-sln) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecologic Oncology 138 (2015) 41 45
49 Touhami et al. Predictors of non-sentinel lymph node (non-sln) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecologic Oncology 138 (2015) 41 45
50 Long-term outcomes , 507 MIS EC cases P<0.001 P<0.001 P 1.0 Leitao et al. Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecol Oncol Apr;129(1):38-41.
51 Prior to SLN Since SLN Rate of Full Lymphadenectomy 65% 23% Median Operative Time 1 hr 40 min Median Lymph nodes removed 20 7
52 SLN algorithm vs comprehensive LND Intermediate Risk: Endometrioid MI>50% High-Risk; Clear cell, Serous Intermediate-risk High-risk Pelvic LN removed, median PALN removed, median LND (N=107) SLN (N=82) p LND (N=103) SLN (N=120) 35 (27-45) 10 (4-14) < (26-41) 11 (5-16) < (12-23) 5 (2-9) < (11-23) 4 (3-8) <0.001 p Stage IIIC 28% 35.4% % 22.5% 0.57 Ducie SGO 2015
53 SLN Algorithm vs Selective LND (1135 low risk cases E<50%MI): SLN (N=642) LND (N=493) p Pelvic Nodes removed 93% 58% <0.001 Pelvic Nodes + 5.1% 2.6% of the 31 SLN+ were ITC PALN + 0.8% 1% 0.75 Significance? Same Survival but more trt? Stage IIIC 5.6% 2.8% 0.02 Adjuvant EBRT and/or Chemo +/- Brachy 8.2% 4.6% < y PFS 94.9% 96.8% y Nodal-Free Recurrence 99.6% 99.6% y DSS 100% 98.8% 0.03 Erikkson SGO 2015 Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion Article in press. Online dec 2015 gynecol oncol
54 Senti-Endo SLN - SLN+ P value EBRT 30% 78.5% Chemotherapy 12.5% 50% /16 SLN+ detected by ultrastaging 50- mo RFS 84.7% % adj trt 36% adj trt Daraï E, Dubernard G, Bats AS, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, Ballester M. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of thesenti-endo study. Gynecol Oncol Jan;136(1):54-9
55 Proficiency Preferred detection rate >80-90% Acceptable FNR <5% ~30 cases/surgeon Detection rate increased from 77% to 94% (p 0.033) Khoury-Collado F, Glaser GE, Zivanovic O, et al. Improvingsentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 2009;115:
56 SGO statement November 2015 SLN mapping with adherence to a surgical algorithm and pathologic ultrastaging is a reasonable staging strategy that provides information on nodal metastasis and potentially reduces morbidity in patients with apparent uterine confined endometrial cancer gynecologic oncologists should consider continuing to perform full lymphadenectomy while their individual experience with SLN mapping is accrued (at least cases), and possibly until their detection rate for metastasis can be documented within the suggested breast SLN guidelines
57 insufficient data to suggest that the upper aortic lymph nodes (above the inferior mesenteric artery) can be reliably mapped using current cervical injection techniques. Decisions regarding the performance of paraaortic lymphadenectomy should continue to be determined by the tumor histology, intraoperative analysis of the primary tumor, and status of pelvic lymph nodes at surgery
58 NCCN SLN staging can be considered for the surgical staging of apparent uterine-confined malignancy when there is no metastasis demonstrated by imaging studies or no obvious extrauterine disease by exploration
59 What to do with a SLN+ Frozen on SLN? Missing micromets and ITC Complete LND? Or just Adjuvant trt? What to do with Micromets and ITCs? PALND? All high risk or only pelvic SLN+
60 Thank you
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationUpdate on sentinel node mapping in uterine cancer: 10-year experience at Memorial Sloan Kettering Cancer Center
bs_bs_banner doi:10.1111/jog.12227 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 327 334, February 2014 Update on sentinel node mapping in uterine cancer: 10-year experience at Memorial Sloan Kettering Cancer
More informationSLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA
Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial
More informationESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital
More informationClinical Significance of Sentinel Lymph Nodes in Patients with Endometrial Cancer
KSGO 2014 Clinical Significance of Sentinel Lymph Nodes in Patients with Endometrial Cancer Daisuke Aoki, M.D., Ph.D. Chairman and Professor, Department of Obstetrics and Gynecology, School of Medicine,
More informationIs it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?
Editorial Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer? Andrea Papadia, Maria Luisa Gasparri, Michael D. Mueller Department of Obstetrics and Gynecology,
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationInternational prospective validation trial of sentinel node biopsy in cervical cancer
Cervix cancer committee International prospective validation trial of sentinel node biopsy in cervical cancer N Abu-Rustum, F Lécuru, P Mathevet, M Plante. F Bonnetain (Statistics) G Chatellier (Clinical
More informationSentinel Node in Endometrial Cancer: a brief review
Sentinel Node in Endometrial Cancer: a brief review Jorge Sánchez-Lander* The rooster of my tree chases with its singing ghosts of shadows and moon specters and spirits Otilio Galíndez, Flor de mayo. Between
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationRochester Minnesota Mayo Clinic
Are There Still Indications for Lymphadenectomy in Endometrial Cancer? A Mariani Mayo Clinic Rochester - MN USA Rochester Minnesota Mayo Clinic 1 Endometrial Cancer Lymphadenectomy Yes or No? Endometrial
More informationUltrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods
International Journal of Gynecological Pathology 00:1 10, Lippincott Williams & Wilkins, Baltimore Copyright r 2017 by the International Society of Gynecological Pathologists Original Article Ultrastaging
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationNewton Wellesley Hospital 2013
Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationPractice of Axilla Surgery
Summer School of Breast Disease 2016 Practice of Axilla Surgery Axillary Lymph Node Dissection & Sentinel Lymph Node Biopsy 연세의대외과 박세호 Contents Anatomy of the axilla Axillary lymph node dissection (ALND)
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationGynecologic Oncology
Gynecologic Oncology 126 (2012) 25 29 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Detection of sentinel lymph nodes in patients
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationThe Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD
The Role of Radiation in the Management of Gynecologic Cancers Scott Glaser, MD Nothing to disclose DISCLOSURE Outline The role of radiation in: Endometrial Cancer Adjuvant Medically inoperable Cervical
More informationLaparoscopic Management of Early Stage Endometrial Cancer. B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G.
Laparoscopic Management of Early Stage Endometrial Cancer B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G. Mage Early Stage of Endometrial Cancer most of cases diagnosed (clinical
More informationEvolving Treatment Strategies for Cervical Cancer
Evolving Treatment Strategies for Cervical Cancer Nadeem Abu-Rustum, MD Memorial Sloan Kettering Cancer Center Evolving Treatment Strategies 1. Surgery 2. Radiation 3. Chemotherapy Incidence of cervix
More informationRole of Surgery in Cervical Cancer & Research Questions
Role of Surgery in Cervical Cancer & Research Questions Arb-aroon Lertkhachonsuk, M.D., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Role of surgery in cervical cancer
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationSentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider
Sentinel Lymph Node Biopsy in Other Tumours Dr. Rona Cheifetz Surgical Oncology Update November 24, 2006 Sentinel Lymph Node Biopsy in Other Tumours: An Operation Looking for an Application Dr. Rona Cheifetz
More informationProspective Study of Sentinel Lymph Node Biopsy Without Further Pelvic Lymphadenectomy in Patients With Sentinel Lymph NodeYNegative Cervical Cancer
ORIGINAL STUDY Prospective Study of Sentinel Lymph Node Biopsy Without Further Pelvic Lymphadenectomy in Patients With Sentinel Lymph NodeYNegative Cervical Cancer Hitoshi Niikura, MD,* Satoshi Okamoto,
More informationPre-operative Evaluation and Implications
Pre-operative Evaluation and Implications Michal Zikan Gynecologic Oncology Center Charles University in Prague, First Faculty of Medicine No recommendation for screening of EC (HNPCC annual biopsies starting
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationCOMPARATIVE ANALYSIS OF COLON AND RECTAL CANCERS IN SENTINEL LYMPH NODE MAPPING
Trakia Journal of Sciences, Vol. 5, No. 1, pp 10-14, 2007 Copyright 2007 Trakia University Available online at: http://www.uni-sz.bg ISSN 1312-1723 Original Contribution COMPARATIVE ANALYSIS OF COLON AND
More informationJournal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1
Journal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1 COMPARATIVE ANALYSIS OF ENDOSCOPICALY SUBMUCOSAL VS. OPEN SURGERY SUB- SEROSAL APPLICATION PATENT BLUE V INTRAOPERATIVE METHOD
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationSurgical Considerations in Breast Cancer treated with Neoadjuvant Therapy
Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Rebecca Warburton MD Department of Surgery, University of British Columbia Mount Saint Joseph Hospital, Providence Health Care
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationOne-Step Nucleic Acid Amplification (OSNA): A. molecular test based on CK19 mrna. concentration for assessment of lymph-nodes
RESEARCH ARTICLE One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mrna concentration for assessment of lymph-nodes metastases in early stage endometrial cancer a1111111111
More informationIntra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer
Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical
More informationCervixcancer. Vad är aktuellt? Jan Persson. Lund. Docent överläkare Dep of OB&G Skane univ hosp Lund Sweden
Cervixcancer Copyright Jan Persson Lund Vad är aktuellt? Jan Persson Docent överläkare Dep of OB&G Skane univ hosp Lund Sweden Controversies Preop selection related stage ( stage 1b1>= 2 cm) Neoadjuvant
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationUltrasound or FNA for Predicting Node Positive in Breast Cancer
Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital
More informationSENTINEL LYMPH NODE CONCEPT IN OESOPHAGEAL CANCER
SENTINEL LYMPH NODE CONCEPT IN OESOPHAGEAL CANCER Sarah K Thompson, M.D. Queenstown ANZGOSA Mtg, 2010 Sentinel Lymph Node (SLN) Sentinel Lymph Node (SLN) Not always on a direct drainage pathway Not always
More informationFeasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study
[ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More informationIs Sentinel Node Biopsy Practical?
Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer
More informationReview Article Lymph Node Assessment in Endometrial Cancer: Towards Personalized Medicine
Obstetrics and Gynecology International Volume 2013, Article ID 892465, 8 pages http://dx.doi.org/10.1155/2013/892465 Review Article Lymph Node Assessment in Endometrial Cancer: Towards Personalized Medicine
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationJournal of Clinical Review & Case Reports
Research Article Journal of Clinical Review & Case Reports Prevention of Lymphatic Complications after Pelvic Laparoscopic Lymphadenectomy by Microporous Polysaccharide Absorbable Hemostat MV Gavrilov
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationParaaortic Lymph Node Dissection
Paraaortic Lymph Node Dissection 가천의대 임소이 Pelvic & paraaortic lymph node dissection Major surgical staging procedure Endometrial cancer, ovarian cancer Cervical cancer: clinical staging Surgical and oncologic
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationIn this Update, I report on the latest US
UPDATE Gynecologic cancer Jason D. Wright, MD Dr. Wright is Sol Goldman Associate Professor, Chief of Division of Gynecologic Oncology, Vice Chair of Academic Affairs, Department of Obstetrics and Gynecology,
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationRisk assessment of lymph node metastasis before surgery in endometrial cancer: Do we need a clinical trial for low-risk patients?
bs_bs_banner doi:10.1111/jog.12281 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 322 326, February 2014 Risk assessment of lymph node metastasis before surgery in endometrial cancer: Do we need a clinical
More informationReview Article Controversies in the Treatment of Early Stage Endometrial Carcinoma
Obstetrics and Gynecology International Volume 2012, Article ID 578490, 8 pages doi:10.1155/2012/578490 Review Article Controversies in the Treatment of Early Stage Endometrial Carcinoma Joshua Z. Press
More informationPara-aortic laparoscopic lymph-node dissection for advanced cervical cancers
Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers P. Mathevet, Hôpital Femme-Mère-Enfant, Bron Lymph-node involvement Is one of the major prognostic factor in gynecologic cancers.
More informationInfluence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer
Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Jason D. Wright, MD, Yongemei Huang, MD/PhD, William M. Burke, MD, et al. Journal Club March 16, 2016 Blaine Campbell-PGY2 Objective
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationCanadian Scientific Journal. Intraoperative color detection of lymph nodes metastases in thyroid cancer
Canadian Scientific Journal 2 (2014) Contents lists available at Canadian Scientific Journal Canadian Scientific Journal journal homepage: Intraoperative color detection of lymph nodes metastases in thyroid
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial
Gynecologic Cancer InterGroup Cervix Cancer Research Network The SHAPE Trial Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients
More informationSavitri Krishnamurthy, MD 1
EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationRESEARCH ARTICLE. Accuracy of Sentinel Node in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.15.6691 Accuracy of Sentinel Node Results in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma Cases RESEARCH ARTICLE Accuracy of Sentinel Node
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationFactors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage
Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures
More informationRESEARCH ARTICLE. Usanee Chatchotikawong 1, Irene Ruengkhachorn 1 *, Chairat Leelaphatanadit 1, Nisarat Phithakwatchara 2. Abstract.
RESEARCH ARTICLE 8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors Usanee Chatchotikawong 1, Irene
More informationPage 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative
Sentinel Node Biopsy: The Past, The Present, and The Future Thomas B. Julian, M.D., F.A.C.S. Associate Professor of Human Oncology Drexel University College of Medicine Director of Breast Surgical Oncology
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationEVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY AXILLARY LYMPH NODE METASTASIS Axillary lymph node metastasis is one of the most
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationSLNB IN CUTANEOUS MELANOMA: VALIDATION OF ITS INTRAOPERATIVE DETECTION THROUGH SPIO IMINEM STUDY
SLNB IN CUTANEOUS MELANOMA: VALIDATION OF ITS INTRAOPERATIVE DETECTION THROUGH SPIO IMINEM STUDY Antonio Piñero-Madrona MD PhD Hospital Clínico Universitario Virgen de la Arrixaca Murcia PROGNOSTIC FACTORS
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationHead & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda
Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationClinical Case Conference Melanoma
Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More information